A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation-Reference-Cited by-同舟云学术

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Published:2020-11 Issue:11 Volume:21 Page:1455-1464
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Prat Aleix,Guarneri Valentina,Paré Laia,Griguolo Gaia,Pascual Tomás,Dieci Maria V,Chic Núria,González-Farré Blanca,Frassoldati Antonio,Sanfeliu Esther,Cejalvo Juan M,Muñoz Montserrat,Bisagni Giancarlo,Brasó-Maristany Fara,Urso Loredana,Vidal Maria,Brandes Alba A,Adamo Barbara,Musolino Antonino,Miglietta Federica,Conte Benedetta,Oliveira Mafalda,Saura Cristina,Pernas Sònia,Alarcón Jesús,Llombart-Cussac Antonio,Cortés Javier,Manso Luis,López Rafael,Ciruelos Eva,Schettini Francesco,Villagrasa Patricia,Carey Lisa A,Perou Charles M,Piacentini Federico,D'Amico Roberto,Tagliafico Enrico,Parker Joel S,Conte Pierfranco

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831;Perez;J Clin Oncol,2014

2. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer;Prat;J Natl Cancer Inst,2014

3. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers;Ferrari;Nat Commun,2016

4. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade;Prat;J Natl Cancer Inst,2019

5. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade;Brasó-Maristany;Nat Commun,2020

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study;The Breast;2024-08

3. Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer;Current Opinion in Oncology;2024-07-25

4. HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial;Clinical Cancer Research;2024-07-12

5. Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response;Journal of Clinical Oncology;2024-07-10